
    
      RA0064 is a Phase 4, multicenter, randomized, 52-week study. All eligible subjects will
      receive open label Cimzia 400 mg at Weeks 0, 2 and 4, followed by Cimzia 200 mg every 2 weeks
      at Weeks 6 to 50 for the treatment of moderate to severe rheumatoid arthritis. All subjects
      will be assessed using the 2 assessment tools: the subject-based Routine Assessment of
      Patient Index (RAPID3) and the investigator-based Clinical Disease Activity Index (CDAI)
    
  